Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

NCT04411641 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1131

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-relapsing Secondary Progressive Multiple Sclerosis

Interventions

DRUG: Tolebrutinib
DRUG: Placebo to match Tolebrutinib

Sponsor

Sanofi